Cancer Biotherapy and Radiopharmaceuticals
Impact Factor & Key Scientometrics

Cancer Biotherapy and Radiopharmaceuticals
Overview

Impact Factor

3.099

H Index

63

Impact Factor

3.636

I. Basic Journal Info

Country

United States
Journal ISSN: 10849785, 15578852
Publisher: Mary Ann Liebert Inc.
History: 1996-ongoing
Journal Hompage: Link
How to Get Published:

Research Categories

Scope/Description:

Cancer Biotherapy and Radiopharmaceuticals is a peer-reviewed journal covering cutting-edge biotherapy and innovative investigations of methods to improve cancer therapy. Includes more selective delivery of drugs, biologicals, radiopharmaceuticals, or other agents, and advances in delivery instrumentation and technology, with the aim of increasing efficacy of therapy and/or decreasing toxicity or improving convenience of therapy. Topics include: • Pre-targeted cancer therapy • Clinical trials in cancer research • Antibody therapy and imaging • Tumor cell vaccines • Radioimmunotherapy • T-cell therapy • Molecular targeted therapy and imaging • Drug resistance

II. Science Citation Report (SCR)



Cancer Biotherapy and Radiopharmaceuticals
SCR Impact Factor

Cancer Biotherapy and Radiopharmaceuticals
SCR Journal Ranking

Cancer Biotherapy and Radiopharmaceuticals
SCImago SJR Rank

SCImago Journal Rank (SJR indicator) is a measure of scientific influence of scholarly journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where such citations come from.

0.716

Cancer Biotherapy and Radiopharmaceuticals
Scopus 2-Year Impact Factor Trend

Note: impact factor data for reference only

Cancer Biotherapy and Radiopharmaceuticals
Scopus 3-Year Impact Factor Trend

Note: impact factor data for reference only

Cancer Biotherapy and Radiopharmaceuticals
Scopus 4-Year Impact Factor Trend

Note: impact factor data for reference only

Cancer Biotherapy and Radiopharmaceuticals
Impact Factor History

2-year 3-year 4-year
  • 2022 Impact Factor
    3.725 3.441 3.227
  • 2021 Impact Factor
    3.636 3.421 3.272
  • 2020 Impact Factor
    2.42 2.582 2.542
  • 2019 Impact Factor
    1.783 1.826 1.795
  • 2018 Impact Factor
    1.726 1.773 1.743
  • 2017 Impact Factor
    1.567 1.643 1.741
  • 2016 Impact Factor
    1.689 2.018 1.99
  • 2015 Impact Factor
    1.926 1.882 1.774
  • 2014 Impact Factor
    2.042 NA NA
  • 2013 Impact Factor
    1.659 NA NA
  • 2012 Impact Factor
    2.006 NA NA
  • 2011 Impact Factor
    2.155 NA NA
  • 2010 Impact Factor
    2.196 NA NA
  • 2009 Impact Factor
    1.551 NA NA
  • 2008 Impact Factor
    1.349 NA NA
  • 2007 Impact Factor
    1.779 NA NA
  • 2006 Impact Factor
    1.911 NA NA
  • 2005 Impact Factor
    1.667 NA NA
  • 2004 Impact Factor
    1.25 NA NA
  • 2003 Impact Factor
    1.935 NA NA
  • 2002 Impact Factor
    1.54 NA NA
  • 2001 Impact Factor
    1.532 NA NA
  • 2000 Impact Factor
    0.875 NA NA
Note: impact factor data for reference only

HIGHEST PAID JOBS

LATEX TUTORIALS

MUST-READ BOOKS


Impact Factor

Impact factor (IF) is a scientometric factor based on the yearly average number of citations on articles published by a particular journal in the last two years. A journal impact factor is frequently used as a proxy for the relative importance of a journal within its field. Find out more: What is a good impact factor?


III. Other Science Influence Indicators

Any impact factor or scientometric indicator alone will not give you the full picture of a science journal. There are also other factors such as H-Index, Self-Citation Ratio, SJR, SNIP, etc. Researchers may also consider the practical aspect of a journal such as publication fees, acceptance rate, review speed. (Learn More)

Cancer Biotherapy and Radiopharmaceuticals
H-Index

The h-index is an author-level metric that attempts to measure both the productivity and citation impact of the publications of a scientist or scholar. The index is based on the set of the scientist's most cited papers and the number of citations that they have received in other publications

63

Cancer Biotherapy and Radiopharmaceuticals
H-Index History